Compare Alcon AG (ALC) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Vanguard Short Term Corporate Bond ETF — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Vanguard Short Term Corporate Bond ETF trades at $78.57. The key difference: Alcon AG pays a 0.54% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Alcon AG is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ALC | VCSH | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Fixed Income |
52-Week High | $92.22 | $80.20 |
52-Week Low | $62.02 | $78.61 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.85 with minimal daily movement (+0.08%). The technical picture is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent news highlights VCSH's competitive advantages including a 4.3% yield and ultra-low 0.03% expense ratio compared to similar bond ETFs. The fund has attracted mixed institutional activity with some firms increasing positions while others reduced exposure.
VCSH offers investors exposure to short-term investment-grade corporate bonds with higher yields than Treasury alternatives, though with slightly more risk. The fund's low costs and monthly distributions make it attractive for income-focused portfolios, but investors face interest rate sensitivity and credit risk from its corporate bond holdings. Current technical weakness suggests potential for near-term price pressure despite the fund's solid fundamental positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
